Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC
| Autor: | Christian Grohé, Frank Griesinger, J. Roeper, Sylke Kurz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Patient Dropouts medicine.drug_class Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Attrition Epidermal growth factor receptor Neoplasm Metastasis Lung cancer Protein Kinase Inhibitors biology business.industry Optimal treatment General Medicine medicine.disease respiratory tract diseases ErbB Receptors Clinical trial 030104 developmental biology Drug Resistance Neoplasm Egfr mutation 030220 oncology & carcinogenesis Mutation biology.protein business Tyrosine kinase |
| Zdroj: | Future Oncology. 17:471-486 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2020-0854 |
| Popis: | Clinical trial and real-world data in non-small-cell lung cancer indicate that 10–60% of patients that progressed on first- or second-generation EGFR-targeting tyrosine kinase inhibitors (TKI) do not receive systemic second-line therapy. In our article, we discuss efficacy, safety and treatment duration with different EGFR-TKIs and stress the need for delivery of the most efficacious therapy in the first-line. We also provide our perspective on analysis of circulating tumor DNA and the role of EGFR-TKI in combined therapies. Finally, we review new therapeutic options to overcome resistance to EGFR-TKI. We believe that overall treatment duration and access to different medications in subsequent lines of therapy should be considered when planning the optimal treatment strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|